Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5384124 | 0.71 | CSNK2A1 (0.31) | — | |
| SCHEMBL218726 | 0.69 | ALDH1A1 (0.54) | CYP1A2 | |
| SCHEMBL8195011 | 0.67 | LMNA (0.36) | TDP1 | |
| SCHEMBL24512546 | 0.67 | CSNK2A1 (0.33) | — | |
| SCHEMBL11366076 | 0.67 | — | — | |
| SCHEMBL13619082 | 0.67 | — | — | |
| SCHEMBL8733589 | 0.67 | ALDH1A1 (0.61) | CYP1A2 | |
| SCHEMBL8895576 | 0.67 | — | — | |
| SCHEMBL8297652 | 0.67 | — | — | |
| SCHEMBL1417542 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11766434-B2 | Pyrimidinone derivatives as CDC7 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-09-26 | — | — | US | disclosed |
| US-11766434-B2 | Pyrimidinone derivatives as CDC7 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-09-26 | — | — | US | disclosed |
| CN-110088100-B | Pyrimidone derivatives as CDC7 inhibitors | 癌症研究科技有限公司 | 2023-02-17 | — | — | CN | disclosed |
| CN-110036006-B | Preparation and use of pyrimidinone derivatives | 癌症研究科技有限公司 | 2022-12-13 | — | — | CN | disclosed |
| US-11020396-B2 | Pyrimidinone derivatives as Cdc7 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-06-01 | — | — | US | disclosed |
| EP-3538523-B1 | PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2021-05-19 | — | — | EP | disclosed |
| US-10919896-B2 | Preparation and uses of pyrimidinone derivatives | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-02-16 | — | — | US | disclosed |
| EP-3515903-B1 | PREPARATION AND USES OF PYRIMIDINONE DERIVATIVES | CANCER RESEARCH TECH LTD (GB) | 2020-10-21 | — | — | EP | disclosed |
| US-20200123157-A1 | PREPARATION AND USES OF PYRIMIDINONE DERIVATIVE | TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC. | 2020-04-23 | — | — | US | disclosed |
| WO-2018087527-A1 | PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-05-17 | — | — | WO | disclosed |
| WO-2018055402-A1 | PREPARATION AND USES OF PYRIMIDINONE DERIVATIVES | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-03-29 | — | — | WO | disclosed |
| CN-105008376-A | Preparation of alkaline earth metal-complexed metal bisamides from metal monoamides | BAYER CROPSCIENCE AG | 2015-10-28 | — | — | CN | disclosed |
| WO-2012062413-A1 | NON METAL TANNING | CLARIANT INTERNATIONAL LTD (CH) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11766434-B2 | Pyrimidinone derivatives as CDC7 inhibitors | CDC7, CDK7, CDK17 | TDP1 475/4885CYP1A2 2582/4885 |
| US-10919896-B2 | Preparation and uses of pyrimidinone derivatives | CDC7, CDK7, CDK17 | TDP1 349/4885CYP1A2 2120/4885 |
| US-11020396-B2 | Pyrimidinone derivatives as Cdc7 inhibitors | CDC7, CDK7, CDK17 | TDP1 475/4885CYP1A2 2582/4885 |
| US-20200123157-A1 | PREPARATION AND USES OF PYRIMIDINONE DERIVATIVE | CDC7, CDK7, CDK17 | TDP1 359/4885CYP1A2 2148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.